First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis Publisher Pubmed

Summary: Early treatment response in MS predicts 5-year outcomes; poor response raises relapse and disability risk, study shows. #MultipleSclerosis #Neurology

Toscano S^{1, 2} ; Spelman T^{3, 4} ; Ozakbas S⁵ ; Alroughani R⁶ ; Chisari CG^{2, 7} ; Lo Fermo S^{2, 7} ; Prat A⁸ ; Girard M⁸ ; Duquette P⁸ ; Izquierdo G⁹ ; Eichau S⁹ ; Grammond P¹⁰ ; Boz C¹¹ ; Kalincik T^{12, 13} Show All Authors

Toscano S^{1, 2}
Spelman T^{3, 4}
Ozakbas S⁵
Alroughani R⁶
Chisari CG^{2, 7}
Lo Fermo S^{2, 7}
Prat A⁸
Girard M⁸
Duquette P⁸
Izquierdo G⁹
Eichau S⁹
Grammond P¹⁰
Boz C¹¹
Kalincik T^{12, 13}
Blanco Y¹⁴
Buzzard K¹⁵
Skibina O¹⁵
Sa MJ^{16, 17}
Van Der Walt A¹⁸
Butzkueven H¹⁸
Terzi M¹⁹
Gerlach O^{20, 21}
Grandmaison F²²
Foschi M^{23, 24}
Surcinelli A²³
Barnett M²⁵
Lugaresi A^{26, 27}
Onofrj M²⁸
Yamout B²⁹
Khoury SJ²⁹
Prevost J³⁰
Lechnerscott J³¹
Maimone D³²
Amato MP^{33, 34}
Spitaleri D³⁵
Van Pesch V³⁶
Macdonell R³⁷
Cartechini E³⁸
De Gans K³⁹
Slee M⁴⁰
Castillotrivino T⁴¹
Soysal A⁴²
Sanchezmenoyo JL⁴³
Laureys G⁴⁴
Van Hijfte L⁴⁴
Mccombe P⁴⁵
Altintas A⁴⁶
Weinstockguttman B⁴⁷
Agueramorales E⁴⁸
Etemadifar M⁴⁹
Ramotello C⁵⁰
John N^{51, 52}
Turkoglu R⁵³
Hodgkinson S⁵⁴
Besora S⁵⁵
Van Wijmeersch B^{56, 57}
Fernandezbolanos R⁵⁸
Patti F^{2, 7}

Source: Neurotherapeutics Published:2025

Abstract

Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated the impact of early therapeutic response on the 5-year prognosis of patients with relapsing-remitting MS (RRMS). We recruited patients from MSBase Registry covering the period between 1996 and 2022. All patients were diagnosed with RRMS and actively followed-up for at least 5 years to explore the following outcomes: clinical relapses, confirmed disability worsening (CDW) and improvement (CDI), EDSS 3.0, EDSS 6.0, conversion to secondary progressive MS (SPMS), new MRI lesions, Progression Independent of Relapse Activity (PIRA). Predictors included demographic, clinical and radiological data, and sub-optimal response (SR) within the first year of treatment. Female sex (HR 1.27; 95 % CI 1.16–1.40) and EDSS at baseline (HR 1.19; 95 % CI 1.15–1.24) were independent risk factors for the occurrence of relapses during the first 5 years after diagnosis, while high-efficacy treatment (HR 0.78; 95 % CI 0.67–0.91) and age at diagnosis (HR 0.83; 95 % CI 0.79–0.86) significantly reduced the risk. SR predicted clinical relapses (HR = 3.84; 95 % CI 3.51–4.19), CDW (HR = 1.74; 95 % CI 1.56–1.93), EDSS 3.0 (HR = 3.01; 95 % CI 2.58–3.51), EDSS 6.0 (HR = 1.77; 95 % CI 1.43–2.20) and new brain (HR = 2.33; 95 % CI 2.04–2.66) and spinal (HR 1.65; 95 % CI 1.29–2.09) MRI lesions. This study highlights the importance of selecting the appropriate DMT for each patient soon after MS diagnosis, also providing clinicians with a practical tool able to calculate personalized risk estimates for different outcomes. © 2025 The Authors

Related Docs

View other Related Docs

1. Disability Accrual in Primary and Secondary Progressive Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2023)

2. Standardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosis, JAMA Neurology (2025)

3. Multiple Sclerosis Severity Score (Msss) Improves the Accuracy of Individualized Prediction in Ms, Multiple Sclerosis Journal (2022)

Experts (# of related papers)

View all Related Experts

Vahid Shaygannejad (18)

Masoud Etemadifar (1)

First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis

Other Related Docs

4. Male Sex Is Independently Associated With Faster Disability Accumulation in Relapse-Onset Ms But Not in Primary Progressive Ms, PLoS ONE (2015)

5. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)

6. Bremso: A Simple Score to Predict Early the Natural Course of Multiple Sclerosis, European Journal of Neurology (2015)

7. Sex As a Determinant of Relapse Incidence and Progressive Course of Multiple Sclerosis, Brain (2013)

8. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)

9. Prognostic Indicators in Pediatric Clinically Isolated Syndrome, Annals of Neurology (2017)

10. External Validation of a Clinical Prediction Model in Multiple Sclerosis, Multiple Sclerosis Journal (2023)

11. Disability Outcomes of Early Cerebellar and Brainstem Symptoms in Multiple Sclerosis, Multiple Sclerosis Journal (2021)

12. Predictors of Treatment Switching in the Big Multiple Sclerosis Data Network, Frontiers in Neurology (2023)

13. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)

14. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)

15. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)

16. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)

17. Corticosteroid Treatment of Multiple Sclerosis Relapses Is Associated With Lower Disability Worsening Over 5 Years, Journal of Neurology, Neurosurgery and Psychiatry (2025)

18. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)

19. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)

20. Promising Effect of Rapamycin on Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2018)

Style	Citing Format
MLA	Toscano S, et al.. "First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis." Neurotherapeutics, vol. 22, no. 2, 2025, pp. -.
APA	Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, Van Der Walt A, ... Patti F (2025). First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 22(2), -.
Chicago	Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, et al.. "First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis." Neurotherapeutics 22, no. 2 (2025): -.
Harvard	Toscano S et al. (2025) 'First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis', Neurotherapeutics, 22(2), pp. -.
Vancouver	Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, et al.. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2025;22(2):-.
BibTex	@article{ author = {Toscano S and Spelman T and Ozakbas S and Alroughani R and Chisari CG and Lo Fermo S and Prat A and Girard M and Duquette P and Izquierdo G and Eichau S and Grammond P and Boz C and Kalincik T and Blanco Y and Buzzard K and Skibina O and Sa MJ and Van Der Walt A and Butzkueven H and Terzi M and Gerlach O and Grandmaison F and Foschi M and Surcinelli A and Barnett M and Lugaresi A and Onofrj M and Yamout B and Khoury SJ and Prevost J and Lechnerscott J and Maimone D and Amato MP and Spitaleri D and Van Pesch V and Macdonell R and Cartechini E and De Gans K and Slee M and Castillotrivino T and Soysal A and Sanchezmenoyo JL and Laureys G and Van Hijfte L and Mccombe P and Altintas A and Weinstockguttman B and Agueramorales E and Etemadifar M and Ramotello C and John N and Turkoglu R and Hodgkinson S and Besora S and Van Wijmeersch B and Fernandezbolanos R and Patti F}, title = {First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis}, journal = {Neurotherapeutics}, volume = {22}, number = {2}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Toscano S AU - Spelman T AU - Ozakbas S AU - Alroughani R AU - Chisari CG AU - Lo Fermo S AU - Prat A AU - Girard M AU - Duquette P AU - Izquierdo G AU - Eichau S AU - Grammond P AU - Boz C AU - Kalincik T AU - Blanco Y AU - Buzzard K AU - Skibina O AU - Sa MJ AU - Van Der Walt A AU - Butzkueven H AU - Terzi M AU - Gerlach O AU - Grandmaison F AU - Foschi M AU - Surcinelli A AU - Barnett M AU - Lugaresi A AU - Onofrj M AU - Yamout B AU - Khoury SJ AU - Prevost J AU - Lechnerscott J AU - Maimone D AU - Amato MP AU - Spitaleri D AU - Van Pesch V AU - Macdonell R AU - Cartechini E AU - De Gans K AU - Slee M AU - Castillotrivino T AU - Soysal A AU - Sanchezmenoyo JL AU - Laureys G AU - Van Hijfte L AU - Mccombe P AU - Altintas A AU - Weinstockguttman B AU - Agueramorales E AU - Etemadifar M AU - Ramotello C AU - John N AU - Turkoglu R AU - Hodgkinson S AU - Besora S AU - Van Wijmeersch B AU - Fernandezbolanos R AU - Patti F TI - First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis JO - Neurotherapeutics VL - 22 IS - 2 SP - EP - PY - 2025 ER -